{"id":"bdp-dpi-2-months","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oropharyngeal candidiasis"},{"rate":"5-15","effect":"Dysphonia"},{"rate":"1-5","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Throat irritation"}]},"_chembl":{"chemblId":"CHEMBL2325227","moleculeType":"Unknown","molecularWeight":"1099.99"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Beclomethasone dipropionate is a topical corticosteroid delivered via dry powder inhaler (DPI) that suppresses inflammatory responses in the respiratory tract by activating glucocorticoid receptors on immune cells and epithelial cells. This reduces mucus production, airway edema, and eosinophil infiltration. The 2-month formulation likely refers to a sustained-release or extended-dosing regimen to improve treatment adherence.","oneSentence":"BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:46.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT01345916","phase":"PHASE3","title":"Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-03","conditions":"Asthma","enrollment":932},{"nctId":"NCT01650441","phase":"PHASE2","title":"Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2012-04","conditions":"Asthma","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clenil® Pulvinal®"],"phase":"phase_3","status":"active","brandName":"BDP DPI 2 months","genericName":"BDP DPI 2 months","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}